Advertisement

Topics

Extended use of AstraZeneca's Brilinta reduces cardiovascular death risk

05:12 EDT 24 Aug 2017 | Pharmafile

New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk of heart attacks by almost a third in patients with a history of such atherothrombotic events.

The findings were derived from sub-analysis of data from the drug’s Phase 3 trial, which examined the effects of Brilinta plus low-dose aspirin in patients who had experienced a myocardial infarction (MI) within two years, or were within one year of stopping anti-platelet treatment with an adenosine diphosphate (ADP) inhibitor.

read more

Original Article: Extended use of AstraZeneca's Brilinta reduces cardiovascular death risk

NEXT ARTICLE

More From BioPortfolio on "Extended use of AstraZeneca's Brilinta reduces cardiovascular death risk"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...